Higher InCRP levels in WHEL participants were significantly associated with an increased risk for additional breast cancer events (HR 1.13, 95% CI 1.03–1.24, p = 0.03, model 3) [27], while the DIANA-2 trial did not observe associations between CRP levels and recurrence [22]. Here, CRP is linked to breast carcinoma.